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Abstract
Background: To determine how the delay in diagnosing celiac disease (CD) has developed during recent decades
and how this affects the burden of disease in terms of health-related quality of life (HRQoL), and also to consider
differences with respect to sex and age.
Methods: In collaboration with the Swedish Society for Coeliacs, a questionnaire was sent to 1,560 randomly
selected members, divided in equal-sized age- and sex strata, and 1,031 (66%) responded. HRQoL was measured
with the EQ-5D descriptive system and was then translated to quality-adjusted life year (QALY) scores. A general
population survey was used as comparison.
Results: The mean delay to diagnosis from the first symptoms was 9.7 years, and from the first doctor visit it was
5.8 years. The delay has been reduced over time for some age groups, but is still quite long. The mean QALY score
during the year prior to initiated treatment was 0.66; it improved after diagnosis and treatment to 0.86, and was
then better than that of a general population (0.79).
Conclusions: The delay from first symptoms to CD diagnosis is unacceptably long for many persons. Untreated CD
results in poor HRQoL, which improves to the level of the general population if diagnosed and treated. By
shortening the diagnostic delay it is possible to reduce this unnecessary burden of disease. Increased awareness of
CD as a common health problem is needed, and active case finding should be intensified. Mass screening for CD
might be an option in the future.
Background
Celiac disease (CD) is a permanent intolerance to gluten
found in wheat, rye and barley. Gluten induces an auto-
immune reaction in the small intestinal mucosa resulting
in inflammation, villous atrophy and malabsorption. The
only effective treatment is a gluten-free diet, which
usually leads to healing of the intestinal mucosa and
recovery from signs and symptoms [1]. Living with
untreated CD is associated with a risk for extensive nega-
tive health consequences [2,3]. In some individuals the
gastrointestinal symptoms are obvious, but frequently the
symptoms are vague, which complicates the identification
of CD cases. This has been shown both by an average
delay of 11-13 years from symptoms to diagnosis [4-6],
and through screening studies. Screening studies have
shown five to 10 undiagnosed cases for every diagnosed
case in some Western European countries [7], four of
five Swedish adults with CD are undiagnosed [8], and
two of three Swedish children with CD are undiagnosed
[9]. In the latter study the prevalence was as high as 3%,
indicating that CD is more common in some populations
than the often mentioned 1%.
Health-related quality of life (HRQoL) as an aspect of
living with CD has been studied frequently [4,5,10-17],
although several questions still remain. The two generic
utility-based instruments, Short Form 36 (SF-36) and
EuroQol 5 Dimensions instrument (EQ-5D), are often
used to measure HRQoL. SF-36 includes eight multi-item
measures that represent different aspects of health [18].
EQ-5D includes both a descriptive system, comprised of
five health-related dimensions (mobility, self-care, usual
activities, pain/discomfort and anxiety/depression) divided
into three levels of severity, and a visual analogue scale
(VAS) for recording overall health [19]. Both instruments
can be translated to a quality-adjusted life year (QALY)
score, which enables comparisons between different
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tion algorithms were first developed for the United States
[20] and the United Kingdom (UK) populations [21], with
the latter commonly used for the Swedish population [22].
For CD, SF-36 is still the most frequently used instrument
[12,14-17], but EQ-5D has become increasingly popular
[5,10].
Studies on treated CD adults have shown divergent
results, with HRQoL either similar to [4,5,10] or worse
than that of the general population [14,17]. Females with
treated CD have been shown to experience worse
HRQoL than males with treated CD [5,11-13]. One study
using EQ-5D collected retrospective HRQoL data from
members of a CD patient organization in the UK [5].
They concluded that the HRQoL before CD diagnosis is
quantitatively similar to that of stroke patients, and that
after initiated treatment it improved and was as good as
that of the general population.
D e s p i t em a n ys t u d i e s ,u n a n s wered questions remain,
due in part to the small size of those studies. Previous stu-
dies have also lacked detailed analyses of various aspects
due to the complex pattern regarding diagnostic delay and
factors such as sex, age and time period for diagnosis. The
aim of this study was to determine how the delay in diag-
nosing CD has developed during recent decades and how
this affects the burden of disease in terms of HRQoL, and
also to consider differences with respect to sex and age.
Methods
Study design
During 2009 we performed a cross-sectional questionnaire
survey, of Swedish adults with CD that was approved by
the Regional Ethical Review Board at Umeå University.
The questionnaire was in Swedish and is accompanied to
this article with an English translation [additional file 1].
For comparison, a questionnaire survey of the general
adult population, “Health On Equal Terms” [23,24], was
used. The latter was performed during 2006 and was
approved by the ethical review board at the Swedish
National Board of Health and Welfare.
Study populations
We studied members of the Swedish Society for Coeliacs
in 2009. The society is open to people with CD and other
food intolerances and is the only one of its kind in the
country. When joining the society, members self-report
their food intolerance. At the time of the study, the
society had 15,659 members reporting CD, 11,094 of
whom were 20 years of age or older. Ludvigsson and col-
leagues defined 29,096 individuals diagnosed with CD in
Sweden, 26,047 who were still alive, between 1969 and
2008, based on biopsy information from a computerized
search of all regional pathology departments [25]. Thus,
the society most likely represents about 60% of all
persons with CD in Sweden. The general adult popula-
tion study consisted of the four most northern Swedish
counties, with a population of 677,777 persons 20 years
of age or older.
Subjects
In total, 1,560 adults with reported CD were invited to
participate, with 65 males and females randomly selected
from each five-year interval from 20 years of age and
above (20-24, 25-29,..., 70-74, and 75 years or older). Out
of 1,122 responders, 1,031 (66%) were eligible for the
study. A reported CD diagnosis based on medical exper-
tise was required for inclusion. As this information was
lacking in the society’s register, when respondents stated
that they had CD, questionnaire information was used to
assess how their CD was diagnosed (blood sample,
biopsy, and/or diet change), and if a medical professional
had recommended adherence to a gluten-free diet.
Ninety-one members did not meet eligibility require-
ments, and they comprised three criteria groups; i) they
did not have CD (n = 34), ii) CD diagnosis uncertain (n =
33), and iii) age and/or sex not consistent based on regis-
ter information and questionnaire responses (n = 24).
Those with uncertain CD were those reporting a self-
diagnosis or that a gluten-free diet had not been recom-
mended by a medical professional. Of eligible responders,
52% (n = 536) were females and the mean age was
52 years (Table 1).
In the general population survey 37,912 randomly
selected persons were invited in strata of age, sex, county
and municipality. In total, 27,809 (73%) responded, 25,797
of whom were 20 years or older [23]. Fifty-three percent
(n = 13,781) were females and the mean age was 52 years.
Questionnaires
Questionnaires were administered by the Swedish Society
for Coeliacs (CD population) and by Statistics Sweden
(general population), both distributed by the postal ser-
vice to the persons’ homes. To facilitate responding in
both studies, a prepaid envelope was included and three
reminders were sent out when needed. Questionnaire
responses were scanned and thereafter checked for
consistency.
The CD questionnaire included a section on delay to
CD diagnosis with questions about the first appearance
of symptoms possibly related to CD, the time of the first
visit to a physician for those symptoms, and time of diag-
nosis. Information that could verify the CD diagnosis and
self-reported degree of compliance with a gluten-free diet
was also collected. We used the EQ-5D instrument to
measure HRQoL. The respondent was asked about the
year prior to initiated treatment for CD, referred to as
pre-treatment, and about today, the time of responding
to the questionnaire. The EQ-5D descriptive system was
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VAS by 914 (89%) respondents.
In the general population, the EQ-5D descriptive system
was completely responded to by 24,460 persons (95%)
aged 20 years or more. EQ-VAS was not included in the
questionnaire.
Statistical analysis
Descriptive statistics were presented using frequency
tables, cross-tabulations, and mean and median values.
Means were compared with Student’s t-test. Delay to diag-
nosis was estimated as the difference between the year of
the first symptoms indicative of CD and the reported year
of diagnosis. For a response of no symptoms before diag-
nosis, the delay was defined as 0 years. The delay from the
first doctor visit was estimated in a similar way. Depen-
dency between the time period for CD diagnosis and the
delay to diagnosis was analyzed with the Cox proportional
hazards model [26]. An exponential of the hazard ratio
above 1 implies a shorter delay from first symptoms to
diagnosis compared to the baseline, which was a diagnosis
before 1980. The descriptive system was translated to a
QALY score using UK weights [21]. Linear regression was
used to study determinants for the QALY score pre-treat-
ment and today. These analyses included sex, current age,
delay from first symptoms indicative of CD to diagnosis
(cutoff set to 2 years), and time period for diagnosis. Sta-
tistical significance was defined at the 5% level. Microsoft
Access was used for data handling, while Stata 11.2 (Stata-
Corp LP, College Station, TX) was used for statistical
analysis.
Results
General characteristics
Of the 1,031 respondents, 52% were females. Mean and
median ages at diagnosis were 39 and 42 years, respec-
tively. Strict compliance with a gluten-free diet was
reported by 979 (96%), and 117 (11%) reported a house-
hold member with CD (Table 1).
Delay to CD diagnosis
The mean delay from the first symptoms indicative of CD
to diagnosis was 9.7 years and the median delay was 4
years (quartiles 1-14 years). From the first visit to a doctor
due to CD-related symptoms to diagnosis, the mean delay
was 5.8 years and the median delay was 1 year (quartiles
0-8 years) (Table 1). Both males and females had a mean
of at least 9 years from the first symptoms to diagnosis for
each 5-year age group from 35-39 up to 65-69 years (data
not shown). Excluding those below 20 years, no age group
had a shorter mean delay than 6 years.
The median delay from symptoms to CD diagnosis has
increased during recent decades, from 1 year for those
diagnosed before 1980, to 5 years if diagnosed during the
period 2005-2009 (data not shown). However, between
t h e s et i m ep e r i o d st h em e d ian age at diagnosis has
increased from 2 years to 46 years (Table 1). Actually, the
delay has decreased for some age groups in recent decades
(Figure 1). This shift in delay is statistically significant for
both males and females aged 20-39 years, and for females
aged 40-59 years diagnosed during the period 2000-2004
as compared to before 1990 (Table 2). However, the delay
is still considerable; for example, in 2005-2009, 56% of
males and 47% of females aged 20-39 had a delay of at
least 5 years (Figure 1). For the age groups 0-19 years and
> 59 years at diagnosis, no statistically significant differ-
ences were observed with respect to delay to diagnosis
when comparing time periods (data not shown).
Health-related quality of life
Within the EQ-5D descriptive system the dimension
anxiety/depression differed most negatively for untreated
CD patients when compared with the general population
(Table 3). The mean QALY score for the CD population
Table 1 Characteristics of celiac disease subjects
n % Mean Median Quartile
1st 3rd
Participants 1,031
Males 495 48
Females 536 52
Age when responding (years) 1,031 52 53 36 67
Duration to diagnosis (years)
First symptom 818 9.7 4 1 14
First doctor visit 853 5.8 1 0 8
Age at diagnosis for the whole
group
945 39 41 27 53
0-19 years 162 17
20-39 years 292 31
40-59 years 353 37
≥ 60 years 138 15
Age at diagnosis in relation to
period for diagnosis
< 1980 67 17 2 1 37
1980-1989 162 27 32 1 45
1990-1999 272 39 43 30 52
2000-2004 221 46 47 33 59
2005-2009 444 45 46 31 59
Compliance with a gluten-free
diet
1,025
Strict 979 96
Non-strict 46 4
Household member with celiac
disease
117 11
Highest educational level 1,013
Primary school 263 26
Secondary school 414 41
University degree 336 33
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Page 3 of 8pre-treatment was 0.66, and it had increased to 0.86
today (p < 0.01) (Table 4). For the general population
the score was 0.79, thus lower than for treated CD
patients. Females reported a significantly lower QALY
score than males, both for the CD population pre-treat-
ment and today (Figure 2), as well as in the general
population (p < 0.01). EQ VAS scores also improved
after diagnosis (p < 0.01), with higher scores for CD
males than for CD females (p < 0.01), both pre-treat-
ment and today (Table 4).
Factors related to health-related quality of life
The QALY scores were significantly lower for CD
females compared to CD males, both pre-treatment and
today (Table 5). A lower QALY score pre-treatment was
also associated with a younger current age, a long delay
Figure 1 Delay to celiac disease diagnosis from first symptoms indicative of the disease. The delay is shown in groups formed by decade
for diagnosis, sex and age at diagnosis (A) 20 to 39 years and (B) 40 to 59 years.
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years), and being diagnosed before 1990 as compared to
being diagnosed more recently (1990-2004) (Table 5).
Discussion
CD patients experienced poor HRQoL pre-treatment,
which improved significantly after diagnosis and treat-
ment. Many experienced a long delay to diagnosis, both
from the first symptoms and from the first visit to a doc-
tor. It is promising that patients diagnosed after 2004
reported better HRQoL than those diagnosed earlier and
that the delay in diagnosis has decreased during recent
decades; however, many still experience too long a delay.
There has been a pronounced increase in median age at
diagnosis, from 2 to 46 years in recent decades, illustrat-
ing that CD has changed from presenting as a childhood
disease to being a disease affecting all ages.
This is a large study with a high response rate. A
strength is that we used a validated HRQoL instrument
and compared HRQoL for the CD population with that
of a general population. The approach of asking CD
respondents about HRQoL both before and after initiated
CD treatment has only been tried once before [5]. Our
study is unique in that results for males and females are
presented separately, and there is a more thorough analy-
sis of factors that affect HRQoL. Further, we add results
Table 2 Relationship between time period for diagnosis and delay from first celiac disease symptoms to diagnosis
Age 20-39 years Age 40-59 years
Males
(n = 142)
Females
(n = 148)
Males
(n = 105)
Females
(n = 150)
Diagnosis year
a HR
b CI
c HR CI HR CI HR CI
< 1990 1 - 1 - 1 - 1 -
1990-1999 1.04 0.65-1.7 1.58 1.0-2.5* 0.81 0.47-1.4 1.29 0.78-2.1
2000-2004 1.71 1.0-2.9* 1.91 1.2-3.2* 1.27 0.71-2.3 1.70 1.0-2.8*
2005-2009 1.36 0.80-2.3 1.54 0.95-2.5 1.20 0.69-2.1 1.46 0.90-2.4
a Cox proportional hazard using those diagnosed before 1990 as comparable group.
b Exponential of the hazard rate.
c Confidence interval.
* Significant difference at 5% level compared to diagnosis before 1990.
Table 3 EQ-5D descriptive system
Celiac disease
(n = 779
a)
General population
(n = 24,460
a)
Dimensions Pre-treatment Today
n% n % n %
Mobility
No problems 720 92 737 95 20,899 85
Some problems 50 6.4 41 5 3,496 14
Severe problems 9 1.1 1 0.1 65 0.3
Self-care
No problems 753 97 768 99 23,912 98
Some problems 14 1.8 7 0.9 442 1.8
Severe problems 12 1.5 4 0.5 106 0.4
Usual activities
No problems 655 84 715 92 21,491 88
Some problems 95 12 54 6.9 2,529 10
Severe problems 29 3.7 10 1.3 440 1.8
Pain/discomfort
No problems 291 37 481 62 9,484 39
Some problems 319 41 278 36 13,658 56
Severe problems 169 22 20 2.6 1,318 5.4
Anxiety/depression
No problems 369 47 546 70 17,045 70
Some problems 314 40 222 28 6,898 28
Severe problems 96 12 11 1.4 517 2.1
a Responded to all dimensions both pre-treatment and today.
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also taking age and sex into consideration.
We believe that our findings are of great value for an
increased understanding of how CD and its diagnostics
affect people, despite some potential biases. We cannot be
sure that our results are representative for the whole
Swedish CD population. However, even if the results
are only valid for responders (66% of invited) to the ques-
tionnaire within our study population (members of the
Swedish Society for Coeliacs which correspond to about
60% of Swedish adults with CD), they nevertheless show
an experienced burden for a sample representing about
40% of Swedish adults with CD, irrespective of age. The
general population in our study is limited to northern
Sweden while the CD population comes from the entire
country. However, regarding HRQoL, there was no statis-
tical difference between persons with CD from the north-
ern part of the country and the rest of Sweden. A recall
bias might appear as some responders had their CD diag-
nosis long ago. This might cause both a low estimate of
HRQoL pre-treatment,a sw e l la sa no v e r e s t i m a t eo f
the delay from first symptoms indicative of CD to CD
Table 4 Quality-adjusted life year (QALY) scores and EQ-VAS
Celiac disease
a General population
a
QALY
b EQ-VAS
Pre-treatment Today Pre-treatment Today QALY
n Mean SD
c Mean SD n Mean SD Mean SD n Mean SD
Males 393 0.71 0.34 0.88 0.18 437 52 27 83 15 11,428 0.81 0.21
Females 386 0.60 0.37 0.84 0.21 477 44 25 80 17 13,032 0.77 0.23
All 779 0.66 0.36 0.86 0.19 914 48 27 81 16 24,460 0.79 0.22
a Responded to all dimensions both pre-treatment and today.
b QALY scores were calculated from responses to the EQ-5D descriptive system.
c Standard deviation.
Figure 2 Quality-adjusted life year (QALY) scores. QALY scores pre-treatment for celiac disease and today, divided into current age and sex.
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fewer episodes of ill health, and therefore previous health
problems might instead be underestimated.
A long diagnostic delay has been shown earlier in several
studies [4-6]. However, awareness of CD has increased in
recent decades and serological testing has been introduced
and improved. Similar to findings in our study, a shor-
tened diagnostic delay over time was found in the UK [5],
but was not observed in Canada [4]. Neither study consid-
ered increasing age at diagnosis, a factor that might affect
their results as well.
The positive effects of diagnosis and treatment we
report here are also supported by others [5,10]. Our
results confirm that CD females experience a lower
HRQoL than males [13]. The difference is even larger
before initiated treatment, which indicates that living
with untreated CD might be a greater burden for females.
It is also interesting that treated CD patients reported a
better HRQoL than the general population. This might
be a result of an altered frame of reference, after experi-
encing poorer health, or due to adapting to a healthier
life style after being diagnosed with a chronic disorder.
Our study subjects reported an unexpectedly high rate of
compliance with a gluten-free diet (96%), and it has been
shown that better compliance is related to a better
HRQoL [11,17,27].
Despite increased awareness in society and in health
care, many CD cases will be missed due to vague symp-
toms. Mass screening for CD has been raised as a possible
option [28]. CD mass screening fulfils most of the listed
criteria for a medical mass screening adapted by WHO
from Wilson and Jungner [29]. However, knowledge con-
cerning the natural history of CD and the cost-effective-
ness of a CD mass screening is lacking [28,30,31]. There
are few health economic evaluation studies of a CD mass
screening. Existing studies indicate that a screening might
be cost-effective [32,33], and that parents’ willingness to
pay for a CD mass screening on average is greater than
the screening cost [34]. It was recently estimated in the
United States that the medical cost for clinically detected
CD patients is reduced by $1764 the year following
diagnosis as compared to the average cost during the pre-
ceding years [35]. The fact that both cost savings and
long-term health complications might differ between clini-
cally diagnosed patients and screening detected CD must
be taken into account, and there is a need for studies on
this particular group [36,37].
Conclusion
Our study shows that for many individuals there is an
unacceptably long delay from the first symptoms to CD
diagnosis. Untreated CD results in poor HRQoL that is
improved to the level of the general population if diag-
nosed and treated. By shortening the diagnostic delay it
is possible to reduce this unnecessary burden of disease.
Increased awareness of CD as a common health pro-
blem is needed, and active case finding should be inten-
sified. Mass screening for CD might be an option in the
future.
Additional material
Additional file 1: Questionnaire-To you, a member of the Swedish
Society for Coeliacs. Your experience is important!.
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